US FDA cracks down on ADHD drug promotion violations
This article was originally published in Scrip
Executive Summary
The US FDAhas cited five makers of attention deficit/hyperactivity disorder medicines for disseminating violative promotions that overstate efficacy in improving outcomes associated with untreated ADHD, broaden the drugs' indications to unapproved uses and fail to include important safety information.